A phenoxy carboxylic acid compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; a pharmaceutical composition comprising the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; and a medicinal use of the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof, for preventing and/or treatment of a metabolic disease (e.g., metabolic syndrome, non-alcoholic fatty liver disease, and/or diabetes mellitus).

A phenoxy carboxylic acid compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; a pharmaceutical composition comprising the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; and a medicinal use of the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof, for preventing and/or treatment of a metabolic disease (e.g., metabolic syndrome, non-alcoholic fatty liver disease, and/or diabetes mellitus).

A fluorine-containing ether compound represented by the following formula.

R.sup.1CH.sub.2R.sup.2[CH.sub.2R.sup.3CH.sub.2R.sup.2].sub.xCH.sub.2R.sup.4

(x is an integer of 1 or 2, R.sup.2 is a perfluoropolyether chain, R.sup.3 is represented by Formula (2), and R.sup.1 and R.sup.4 are each a terminal group having 1 to 50 carbon atoms, which has 1 to 4 polar groups)

##STR00001##

This fluorine-containing ether compound is a fluorine-containing ether compound represented by the following formula:

R.sup.1CH.sub.2R.sup.2(CH.sub.2OCH.sub.2CR.sup.3R.sup.4CH.sub.2OCH.sub.2R.sup.2).sub.zCH.sub.2R.sup.5

(z represents 1 or 2. R.sup.2 is a perfluoropolyether chain. R.sup.1 and R.sup.5 are terminal groups having 1 to 50 carbon atoms and having at least one polar group. R.sup.3 and R.sup.4 may be the same as or different from each other, and are organic groups which do not include a secondary hydroxy group and a tertiary hydroxy group, include one primary hydroxy group, and have 1 to 5 carbon atoms bonded to a tetrasubstituted carbon atom. The organic group may include an ether oxygen atom between the carbon atoms, and a bonding terminal to the tetrasubstituted carbon atom may be an ether oxygen atom.)

A phenoxy carboxylic acid compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; a pharmaceutical composition comprising the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; and a medicinal use of the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof, for preventing and/or treatment of a metabolic disease (e.g., metabolic syndrome, non-alcoholic fatty liver disease, and/or diabetes mellitus).

A phenoxy carboxylic acid compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; a pharmaceutical composition comprising the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; and a medicinal use of the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof, for preventing and/or treatment of a metabolic disease (e.g., metabolic syndrome, non-alcoholic fatty liver disease, and/or diabetes mellitus).

The purpose of the present invention is to provide an alkylating agent that can alkylate a hydroxyl group at 2 position of a synthetic intermediate for an amidite compound in the presence of a base. The present invention provides an alkyl halide that is represented by general formula (I) and can achieve alkylation in the presence of a base.

##STR00001##

[In the formula, X represents a halogen atom, n represents an integer of 1-5, R.sup.1 and R.sup.2 are the same or different and represent a methyl group, an ethyl group, or a hydrogen atom, and EWG represents a cyano group or a SO.sub.2R.sup.3 group (R.sup.3 represents a phenyl group, a C1-10 alkyl group, or a benzyl group which are optionally substituted with a halogen atom, a methyl group, a nitro group, a methoxy group, or a trifluoromethyl group).]

The purpose of the present invention is to provide an alkylating agent that can alkylate a hydroxyl group at 2 position of a synthetic intermediate for an amidite compound in the presence of a base. The present invention provides an alkyl halide that is represented by general formula (I) and can achieve alkylation in the presence of a base.

##STR00001##

[In the formula, X represents a halogen atom, n represents an integer of 1-5, R.sup.1 and R.sup.2 are the same or different and represent a methyl group, an ethyl group, or a hydrogen atom, and EWG represents a cyano group or a SO.sub.2R.sup.3 group (R.sup.3 represents a phenyl group, a C1-10 alkyl group, or a benzyl group which are optionally substituted with a halogen atom, a methyl group, a nitro group, a methoxy group, or a trifluoromethyl group).]

An electrolyte, a secondary battery, and an electric device. The electrolyte comprises a component, a nitrile solvent. The nitrile solvent comprises a compound represented by formula (1): wherein: L is selected from any one of C(R.sub.1R.sub.2), O, Si(R.sub.3R.sub.4), B(R.sub.5), P(R.sub.6R.sub.7R.sub.8), and N(R.sub.9); R.sub.1-R.sub.9 are each independently selected from at least one of H, halogen, substituted or unsubstituted alkyl having 1-3 carbon atoms, alkoxy having 1-3 carbon atoms, amino, and cyano, and R.sub.1 and R.sub.2 are not cyanos and H; R.sub.11 is an alkane chain containing 1-4 carbon atoms; R.sub.12-R.sub.14 are each independently selected from at least one of H, halogen, substituted or unsubstituted alkyl having 1-3 carbon atoms, alkoxy having 1-3 carbon atoms, amino, and cyano; and when L is C(R.sub.1R.sub.2), R.sub.12-R.sub.14 are not cyanos.

An electrolyte, a secondary battery, and an electric device. The electrolyte comprises a component, a nitrile solvent. The nitrile solvent comprises a compound represented by formula (1): wherein: L is selected from any one of C(R.sub.1R.sub.2), O, Si(R.sub.3R.sub.4), B(R.sub.5), P(R.sub.6R.sub.7R.sub.8), and N(R.sub.9); R.sub.1-R.sub.9 are each independently selected from at least one of H, halogen, substituted or unsubstituted alkyl having 1-3 carbon atoms, alkoxy having 1-3 carbon atoms, amino, and cyano, and R.sub.1 and R.sub.2 are not cyanos and H; R.sub.11 is an alkane chain containing 1-4 carbon atoms; R.sub.12-R.sub.14 are each independently selected from at least one of H, halogen, substituted or unsubstituted alkyl having 1-3 carbon atoms, alkoxy having 1-3 carbon atoms, amino, and cyano; and when L is C(R.sub.1R.sub.2), R.sub.12-R.sub.14 are not cyanos.